JPMorgan Chase & Co. Forecasts Strong Price Appreciation for Guardant Health (NASDAQ:GH) Stock

Guardant Health (NASDAQ:GH) had its target price lifted by equities researchers at JPMorgan Chase & Co. from $120.00 to $130.00 in a research report issued to clients and investors on Friday,Benzinga reports. The firm presently has an “overweight” rating on the stock. JPMorgan Chase & Co.‘s target price suggests a potential upside of 26.09% from the company’s current price.

Other equities analysts have also issued reports about the stock. Mizuho set a $135.00 target price on shares of Guardant Health in a research report on Friday, January 9th. Stifel Nicolaus increased their price target on shares of Guardant Health from $120.00 to $130.00 and gave the stock a “buy” rating in a research note on Friday. Robert W. Baird started coverage on shares of Guardant Health in a research report on Tuesday. They set an “outperform” rating and a $120.00 price objective on the stock. Wells Fargo & Company upped their target price on shares of Guardant Health from $120.00 to $125.00 and gave the company an “overweight” rating in a report on Friday. Finally, Morgan Stanley increased their target price on shares of Guardant Health from $105.00 to $130.00 and gave the stock an “overweight” rating in a research note on Monday, December 1st. Twenty-one equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Guardant Health currently has a consensus rating of “Moderate Buy” and a consensus price target of $117.43.

Guardant Health Stock Performance

GH opened at $103.10 on Friday. Guardant Health has a one year low of $34.88 and a one year high of $120.74. The stock has a market capitalization of $12.99 billion, a P/E ratio of -31.15 and a beta of 1.63. The business’s 50-day simple moving average is $106.69 and its 200-day simple moving average is $86.22.

Guardant Health (NASDAQ:GH) last announced its earnings results on Thursday, February 19th. The company reported ($0.50) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.43) by ($0.07). The company had revenue of $281.27 million during the quarter, compared to analysts’ expectations of $269.74 million. The firm’s revenue for the quarter was up 39.4% on a year-over-year basis. During the same period in the previous year, the business posted ($0.62) earnings per share. On average, equities research analysts forecast that Guardant Health will post -2.9 EPS for the current fiscal year.

Insider Buying and Selling

In other news, Director Medina Manuel Hidalgo sold 1,250 shares of Guardant Health stock in a transaction dated Monday, December 8th. The shares were sold at an average price of $105.00, for a total value of $131,250.00. Following the sale, the director owned 797 shares of the company’s stock, valued at $83,685. The trade was a 61.06% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Amirali Talasaz sold 100,000 shares of the stock in a transaction dated Monday, December 8th. The stock was sold at an average price of $105.05, for a total transaction of $10,505,000.00. Following the transaction, the chief executive officer directly owned 168,223 shares of the company’s stock, valued at $17,671,826.15. This represents a 37.28% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders have sold 434,511 shares of company stock worth $45,580,887. 6.10% of the stock is currently owned by insiders.

Institutional Trading of Guardant Health

Several hedge funds have recently modified their holdings of the business. V Square Quantitative Management LLC purchased a new stake in shares of Guardant Health in the fourth quarter valued at approximately $27,000. Chesapeake Asset Management LLC acquired a new stake in Guardant Health in the fourth quarter valued at $28,000. Thurston Springer Miller Herd & Titak Inc. purchased a new stake in shares of Guardant Health during the 4th quarter worth $31,000. Elyxium Wealth LLC acquired a new position in shares of Guardant Health during the 4th quarter worth $35,000. Finally, Parallel Advisors LLC increased its holdings in shares of Guardant Health by 164.7% in the 4th quarter. Parallel Advisors LLC now owns 352 shares of the company’s stock valued at $36,000 after purchasing an additional 219 shares in the last quarter. 92.60% of the stock is owned by institutional investors and hedge funds.

Trending Headlines about Guardant Health

Here are the key news stories impacting Guardant Health this week:

• Positive Sentiment: Multiple brokerages raised price targets and maintained buy/overweight ratings (Leerink to $180, JPMorgan to $130, Wells Fargo to $125, BTIG to $145, Canaccord to $135), signaling analyst confidence in upside from current levels. Analyst Raises Coverage
• Positive Sentiment: Q4 revenue beat and strong growth: Guardant reported $281.3M in Q4 revenue, +39% YoY and above consensus; management issued FY2026 revenue guidance around $1.3B, above Street expectations — a growth signal for core oncology testing. Press Release
• Positive Sentiment: Research coverage expansion: Robert W. Baird initiated coverage, which can broaden institutional interest and trading liquidity. Coverage Start
• Neutral Sentiment: Conference call and transcript available — provides detail on cadence of test volume, reimbursement progress and product roadmap; useful for digging into guidance assumptions. Earnings Transcript
• Neutral Sentiment: Market materials (slide deck, press release) posted for investors to verify segment trends and margin assumptions. Slide Deck / Press Release
• Neutral Sentiment: Short-interest data flagged a “significant increase” entry but shows 0 shares / NaN in the feed — the published data appears inconsistent, so short-interest impact is unclear. Short Interest Note
• Negative Sentiment: EPS miss: GAAP loss of ($0.50) vs. consensus (~($0.43)), which disappointed some investors despite revenue upside and may have pressured the stock near the close. Earnings Reaction
• Negative Sentiment: Management left EPS guidance effectively blank in the release (revenue guidance given but no numeric EPS target), which can create uncertainty around near-term profitability expectations. Guidance Details

Guardant Health Company Profile

Guardant Health, Inc is a precision oncology company specializing in blood-based cancer diagnostics. Founded in 2012 and headquartered in Redwood City, California, the company develops non-invasive tests that use circulating tumor DNA (ctDNA) to profile genomic alterations in patients with solid tumors. Guardant Health’s mission is to advance cancer care by providing actionable data to clinicians, pharmaceutical partners and researchers worldwide.

The company’s flagship product, Guardant360, is a next-generation sequencing (NGS) assay designed to detect mutations, copy number variations and select fusions in more than 70 cancer-related genes.